Equities analysts predict that Rockwell Medical Inc (NASDAQ:RMTI) will announce ($0.13) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Rockwell Medical’s earnings, with estimates ranging from ($0.13) to ($0.12). Rockwell Medical posted earnings of ($0.14) per share in the same quarter last year, which suggests a positive year over year growth rate of 7.1%. The company is scheduled to issue its next quarterly earnings results on Wednesday, August 8th.
On average, analysts expect that Rockwell Medical will report full year earnings of ($0.38) per share for the current year, with EPS estimates ranging from ($0.49) to ($0.26). For the next financial year, analysts anticipate that the business will post earnings of $0.04 per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Rockwell Medical.
Get Rockwell Medical alerts:
Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Thursday, May 10th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. The company had revenue of $14.95 million during the quarter. Rockwell Medical had a negative net margin of 48.06% and a negative return on equity of 76.49%.
Several equities research analysts have recently weighed in on RMTI shares. BidaskClub raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Thursday, May 17th. Finally, ValuEngine downgraded shares of Rockwell Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd.
Several institutional investors and hedge funds have recently added to or reduced their stakes in RMTI. MetLife Investment Advisors LLC bought a new stake in shares of Rockwell Medical in the 4th quarter worth about $110,000. Goldman Sachs Group Inc. increased its position in shares of Rockwell Medical by 117.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 27,139 shares of the company’s stock worth $158,000 after purchasing an additional 14,648 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Rockwell Medical during the 4th quarter valued at about $217,000. Schwab Charles Investment Management Inc. grew its position in shares of Rockwell Medical by 21.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 95,900 shares of the company’s stock valued at $500,000 after buying an additional 17,200 shares during the last quarter. Finally, Deutsche Bank AG grew its position in shares of Rockwell Medical by 107.7% during the 4th quarter. Deutsche Bank AG now owns 121,202 shares of the company’s stock valued at $704,000 after buying an additional 62,842 shares during the last quarter. 21.21% of the stock is owned by institutional investors.
RMTI opened at $5.68 on Thursday. The stock has a market capitalization of $307.50 million, a PE ratio of -11.14 and a beta of 2.18. Rockwell Medical has a 1-year low of $4.84 and a 1-year high of $8.70.
About Rockwell Medical
Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.
Get a free copy of the Zacks research report on Rockwell Medical (RMTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com